Pages that link to "Q29619648"
Jump to navigation
Jump to search
The following pages link to Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status (Q29619648):
Displaying 50 items.
- BRAF V600E (Q21851559) (← links)
- Markers of resistance to anti-EGFR therapy in colorectal cancer (Q24598640) (← links)
- Predictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of Options (Q26738655) (← links)
- Treatment of Metastatic Colorectal Cancer: Standard of Care and Future Perspectives (Q26738801) (← links)
- Genomic diversity of colorectal cancer: Changing landscape and emerging targets (Q26739052) (← links)
- Current targeted therapies in the treatment of advanced colorectal cancer: a review (Q26740067) (← links)
- Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials? (Q26744088) (← links)
- Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer (Q26747329) (← links)
- Treatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancer (Q26747335) (← links)
- MicroRNAs: Novel immunotherapeutic targets in colorectal carcinoma (Q26747339) (← links)
- Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer (Q26748924) (← links)
- Molecular testing to optimize therapeutic decision making in advanced colorectal cancer (Q26749012) (← links)
- Serrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapy (Q26751035) (← links)
- Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS (Q26766535) (← links)
- Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances (Q26768427) (← links)
- Clinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancer (Q26769958) (← links)
- New therapeutic strategies for BRAF mutant colorectal cancers (Q26772277) (← links)
- Biomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancer (Q26774605) (← links)
- Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review (Q26775522) (← links)
- Treatment-related gastrointestinal toxicities and advanced colorectal or pancreatic cancer: A critical update (Q26778004) (← links)
- Colorectal cancer: Metastases to a single organ (Q26778009) (← links)
- Molecular profiling in the treatment of colorectal cancer: focus on regorafenib (Q26778296) (← links)
- The role of N-glycans in colorectal cancer progression: potential biomarkers and therapeutic applications (Q26779166) (← links)
- State of the art management of metastatic gastroesophageal cancer (Q26779217) (← links)
- New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS? (Q26796348) (← links)
- Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer (Q26798284) (← links)
- Gastrointestinal cancers in the era of theranostics: Updates and future perspectives (Q26801215) (← links)
- Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer (Q26821956) (← links)
- Personalized treatment for advanced colorectal cancer: KRAS and beyond (Q26822817) (← links)
- Management of colorectal cancer (Q26823550) (← links)
- Anti-angiogenic therapies for metastatic colorectal cancer: current and future perspectives (Q26826817) (← links)
- Toward a Molecular Classification of Colorectal Cancer: The Role of BRAF (Q26827212) (← links)
- Let-7 microRNA-binding-site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta-analysis (Q26827474) (← links)
- Recent applications of chemosensitivity tests for colorectal cancer treatment (Q26851075) (← links)
- Pulmonary metastasectomy for colorectal cancer: how many nodules, how many times? (Q26859632) (← links)
- Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance (Q26866517) (← links)
- Extravascular use of drug-eluting beads: a promising approach in compartment-based tumor therapy (Q27000814) (← links)
- Future directions for monitoring treatment response in colorectal cancer (Q27008428) (← links)
- Targeted therapy in advanced bladder cancer: what have we learned? (Q27009469) (← links)
- Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (Q27015224) (← links)
- Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement (Q27020973) (← links)
- Review of systemic therapies for locally advanced and metastatic rectal cancer (Q27021105) (← links)
- Perfusion CT imaging of colorectal cancer (Q27022129) (← links)
- Treatment of metastatic colorectal cancer: focus on panitumumab (Q27022954) (← links)
- Monoclonal antibodies for the treatment of cancer (Q27025966) (← links)
- Management of locally advanced and metastatic colon cancer in elderly patients (Q27026129) (← links)
- How to select the optimal treatment for first line metastatic colorectal cancer (Q27026516) (← links)
- Epidermal growth factor receptor inhibitors: coming of age (Q27030769) (← links)
- Identification of clinically relevant molecular subtypes in colorectal cancer: the dawning of a new era (Q27693248) (← links)
- HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients (Q27852057) (← links)